CIK 0001714899
- Large accelerated filer
Denali Therapeutics Inc.
Sign in to watch- Ticker
- DNLI
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 463872213
- Phone
- +1 650-866-8547
- Business address
- 161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA, 94080
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Open-market sale COO and Secretary sold 7,500 shares at an average $22.05 ($165,350)
- 4 Open-market sale Chief Medical Officer sold 17,500 shares at an average $22.85 ($399,901)
- 4/A Open-market sale Chief Medical Officer sold 36,912 shares at an average $25.44 ($938,976)
- 4 Open-market sale President and CEO sold 18,334 shares at an average $24.20 ($443,744)
- 4 Open-market sale COO and Secretary sold 7,500 shares at an average $28.05 ($210,396)
- 4 Other disposition 10% owner disposed of 158,764 shares (other)
- 4 Open-market sale Chief Medical Officer sold 9,588 shares at an average $26.35 ($252,678)
- 4 Open-market sale Chief Medical Officer sold 36,805 shares at an average $25.44 ($936,285)
- 4 Open-market sale President and CEO sold 18,333 shares at an average $25.03 ($458,800)
- 4 Open-market sale Chief Medical Officer sold 1,000 shares at $25.01 ($25,010)
- 4 Open-market sale COO and Secretary sold 7,500 shares at an average $22.58 ($169,313)
- 4 Open-market sale Chief Medical Officer sold 17,500 shares at an average $22.17 ($388,000)
Page 18 of 22 · 436 filings